Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/13/2010US20100120855 Macrocylic inhibitors of hepatitis c virus
05/13/2010US20100120854 Tgf-beta inhibitors
05/13/2010US20100120853 Derivatives of Hypoestoxide and Related Compounds
05/13/2010US20100120852 Aroyl-piperidine derivatives and method of treating disorders induced by substance p
05/13/2010US20100120851 Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
05/13/2010US20100120850 Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases
05/13/2010US20100120849 Compositions for Treating Hyperproliferative Vascular Disorders and Cancers
05/13/2010US20100120848 Stable pharmaceutical formulations of montelukast sodium
05/13/2010US20100120847 Styrylquinolines, their process of preparation and their therapeutic uses
05/13/2010US20100120846 Trpv1 antagonists
05/13/2010US20100120845 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
05/13/2010US20100120844 Tetrahydroisoquinoline compound
05/13/2010US20100120843 Pharmaceutical composition for treating alcohol-induced liver injury comprising (4s,5s)-5-fluoromethyl-5-hydroxy-4-(amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof
05/13/2010US20100120842 Neurogenesis by muscarinic receptor modulation
05/13/2010US20100120841 Benzimidazole compound and pharmaceutical use thereof
05/13/2010US20100120840 tyrosine kinase inhibitors such as 1-Phenyl-ethyl)-(2-phenyl-3H-imidazo[4,5-b]pyridin-6-yl)-amine, used in the prevention and therapy of transplant rejection, inflammatory bowel disease, arthritis, psoriasis, restenosis, asthma, stroke, osteoporosis, cancer, Alzheimer's and Parkinson's disease
05/13/2010US20100120839 Pyrazoles useful in the treatment of inflammation
05/13/2010US20100120838 Compounds for the treatment of inflammatory disorders
05/13/2010US20100120837 Method of treating a mucosal and/or dermal associated condition
05/13/2010US20100120836 Method of treating a dermal and/or mucosal associated condition
05/13/2010US20100120835 Pharmaceutical cream with reduced imiquimod impurities at four months using refined oleic acid
05/13/2010US20100120834 Reduction of imiquimod impurities at four months using refined oleic acid
05/13/2010US20100120833 Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation (at least six months storage)
05/13/2010US20100120832 Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation (at least four months storage)
05/13/2010US20100120831 Methods for improving imiquimod availability at two months, four months and six months between refined and compendial
05/13/2010US20100120830 Pharmaceutical cream having similar or less levels of imiquimod impurity formation as cream with bha (comparator)
05/13/2010US20100120829 X-fold less imiquimod impurities at six months between refined and compendial
05/13/2010US20100120828 Method of inducing interferon biosynthesis
05/13/2010US20100120827 X-fold less imiquimod impurities at two months between refined and compendial
05/13/2010US20100120826 Method of inducing cytokine biosynthesis
05/13/2010US20100120825 Method of treating mollescum contagiosum
05/13/2010US20100120824 Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation
05/13/2010US20100120823 Method of treating basal cell carcinoma
05/13/2010US20100120822 Method of controlling formation of imiquimod impurities (bha comparator)
05/13/2010US20100120821 Method of treating genital or peri-anal warts
05/13/2010US20100120820 Method of treating actinic keratosis
05/13/2010US20100120819 Method of reducing imiquimod impurity formation
05/13/2010US20100120818 Substituted tetrahydropyrroloquinolines
05/13/2010US20100120817 Azonafide derived tumor and cancer targeting compounds
05/13/2010US20100120816 Camptothecin derivatives with antitumor activity
05/13/2010US20100120815 Stable solid preparation containing 4,5-epoxymorphinan derivative
05/13/2010US20100120814 Crystalline and Amorphous Forms of Naltrexone Hydrochloride
05/13/2010US20100120813 Peripheral opioid receptor antagonists and uses thereof
05/13/2010US20100120812 Medicinal Compositions Comprising Buprenorphine And Naltrexone
05/13/2010US20100120811 Long-acting injectable analgesic formulations for animals
05/13/2010US20100120810 Compounds and methods for modulating rho gtpases
05/13/2010US20100120809 Aryl heterocyclic cgrp receptor antagonists
05/13/2010US20100120808 Spirocyclic heterocyclic derivatives and methods of their use
05/13/2010US20100120807 Compounds and compositions as modulators of gpr119 activity
05/13/2010US20100120806 Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
05/13/2010US20100120805 Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors
05/13/2010US20100120804 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
05/13/2010US20100120803 3,4-dihydroquinazoline derivatives
05/13/2010US20100120802 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production
05/13/2010US20100120801 Akt and p70 s6 kinase inhibitors
05/13/2010US20100120800 Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
05/13/2010US20100120799 Purine derivatives as immunomodulators
05/13/2010US20100120798 Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety
05/13/2010US20100120797 Purinyl derivatives and their use as potassium channel modulators
05/13/2010US20100120796 Compositions and methods for treatment and prevention of hyperuricemia related health consequneces
05/13/2010US20100120795 Powders for reconstitution
05/13/2010US20100120794 Cycloalkylamino Acid Derivatives
05/13/2010US20100120793 Pyrrolidines
05/13/2010US20100120792 Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof
05/13/2010US20100120791 Cyclohexyl sulfonamide derivatives
05/13/2010US20100120790 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity
05/13/2010US20100120789 Compound
05/13/2010US20100120788 Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
05/13/2010US20100120787 Modification of amyloid-beta load in non-brain tissue
05/13/2010US20100120786 Piperazine Derivatives
05/13/2010US20100120785 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists
05/13/2010US20100120784 Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
05/13/2010US20100120783 Melanocortin receptor agonists
05/13/2010US20100120782 Endoparasiticidal gel composition
05/13/2010US20100120781 Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function
05/13/2010US20100120780 Treatments for premature ejaculation in humans
05/13/2010US20100120779 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
05/13/2010US20100120778 Quinoxaline-based lxr modulators
05/13/2010US20100120777 Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin
05/13/2010US20100120776 Carbocysteine medical foods
05/13/2010US20100120775 Farnesoid X Receptor Agonists
05/13/2010US20100120774 (2R,3 S)-3 ((2-chloro-4-pyrimidinyl)amino)-4-(3,5-difluorophenyl)-1 (((4'S)-6'-(2,2-dimethylpropyl)-3', 4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)-2-butanol, used for the treatment Alzheimer's disease, cognitive deficits and impairment, and schizophrenia
05/13/2010US20100120773 Method of treating disorders mediated by the fibroblast growth factor receptor
05/13/2010US20100120772 P38 kinase inhibitors
05/13/2010US20100120771 Aurora kinase inhibitors from an encoded small molecule library
05/13/2010US20100120770 Thiazolyl compounds useful as kinase inhibitors
05/13/2010US20100120769 Cyclohexyl piperazinyl methanone derivatives
05/13/2010US20100120768 Methods, kits, and compositions for generating new hair follicles and growing hair
05/13/2010US20100120767 Pyrimidothiophene Compounds
05/13/2010US20100120766 Substituted Pteridines
05/13/2010US20100120765 Pyrazolyl substituted xanthines
05/13/2010US20100120764 Di-substituted amides for enhancing glutamatergic synaptic responses
05/13/2010US20100120763 Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
05/13/2010US20100120762 Triazine derivatives as inhibitors of phosphodiesterases
05/13/2010US20100120761 Bicyclic Heterocyclic Compounds as FGFR Inhibitors
05/13/2010US20100120760 Benzofuran-carboxamide derivatives as antiviral agents
05/13/2010US20100120759 Azadecalin glucocorticoid receptor modulators
05/13/2010US20100120758 Reverse-turn mimetics and method relating thereto
05/13/2010US20100120757 Pyrazolone derivatives as pde4 inhibitors
05/13/2010US20100120756 Phenothiazine modulators of h1 receptors
1 ... 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 ... 7860